Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

19

Jan 2021

TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases

TenNor Therapeutics Limited a clinicalstage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses

19

Jan 2021

Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy

Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel AdenoAssociated Virus AAV vectorsleveraging Cure Genetics proprietary VELPTM platform to develop nextgeneration gene therapies

18

Jan 2021

ARTMS and Terix Pharmaceuticals Announce Successful Manufacture of PSMA-11 Using Cyclotron 68Ga from Solid Target

RTMS Incand Terix Pharmaceuticals Limited Terixs TLX prostate cancer imaging product using multiple curry units of gallium Ga manufactured on a cyclotron through a proprietary Quantum Irradiation System QIS solidstate targeting system

16

Jan 2021

Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19

Jubilant Therapeutics Inc a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases announced a collaboration with The Wistar Institute an international leader in biomedical research

press releasesRead more...

19

Jan 2021

Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

Tessa Therapeutics Tessa a clinicalstage cell therapy company developing nextgeneration cancer treatments for hematological malignancies and solid tumors today announced that the European Medicines Agency EMA has granted PRiority MEdicines PRIME designation

19

Jan 2021

Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics Inc a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseasesannounced dose administration for the first patient in a Phase a clinical study of the companys lead drug candidate STP for the treatment of cutaneous basal ce...

18

Jan 2021

Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics Inc a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases announced dose administration for the first patient in a Phase a clinical study of the companys lead drug candidate STP for the treatment of cutaneous basal c...

18

Jan 2021

Everest Medicines Announces Amended Agreement with Spero Therapeutics

Everest Medicines a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia

EventsRead more...

19 - 21

Jan 2021

Cannabinoid Derived Pharmaceuticals Summit

Hanson Wade
Hilton London Kensington

25 - 26

Jan 2021

TOP ARTICLES

  • 3

    Personalised Therapy

    Drugs can be formulated in the form of tablets pellets emulsion cream and many others for patient consumption...

KNOWLEDGE BANK

  • Interviews

    Thomson Reuters

    Senior Vice President

    We believe publications such as Pharmafocus Asia are essential in providing professionals with insights into the dynamic and evolving trends of the Pharma industry
  • Articles

    Endocrine Disrupting Compounds (EDCs)

    The accessibility of sufficient pure water in terms of both quantity and quality is vital for human existence Unfortunately our hydric resources have become seriously polluted due to the continuous expansion of industries and urbanisation

  • Techno Trends

    BioAsia 2013

    Exploring the NEXT trends in Biotechnology Biologics and Biosimilars The emerging global shift from pharmaceutical drugs to biopharmaceuticals and its impact on human life and biobusiness clearly underlines the dynamic and self evolving nature of Lifesciences B

  • White Papers

    Crippled by Cost? CMO Quo Vadis

    Introduction The global CMO market is said to reach USD billion by Patent expiry of drugs stringent price regulations especially in Europe US to purchase drugs from pharma companies Government budget cuts for pharma RD these are the forces which are expected to reshape the future of pharma and the CMO industry At least manufacturing facilities owned by pharma companies were shut dow

EDITORIAL SECTION

  • EXPERT Talk

    PHARMA LOGISTICS TRENDS

    Pharma logistics is undergoing profound change throughout Asia as the ageing population drives a growing need for new pharma solutions together with s...